Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus | Citedby Results | Archives of Pathology & Laboratory Medicine

Skip to Main Content

Skip Nav Destination

Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus

Arch Pathol Lab Med (2023) 147 (1): 79–86.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Anaplastic large cell lymphoma: unusual clinical and pathologic findings: A report of the 2023 SH-EA4HP Lymphoma Workshop

Jie Xu
Eric D Hsi
Roberto N Miranda
Mario L Marques-Piubelli
L Jeffrey Medeiros
Andrew L Feldman

American Journal of Clinical Pathology (2025) 164 (1): 110.

Challenges of CD30 expression and its impact on targeted treatment responses in non-Hodgkin lymphoma: New perspectives for evaluation and validation

Yunfei Shi
Xianghong Li

Pathology - Research and Practice (2025) 272: 156098.

Recent Advances in Understanding the Clinical Responses of Brentuximab Vedotin in Lymphoma and the Correlation with CD30 Expression

Wen Chen
Zhihong Zhang

OncoTargets and Therapy (2025) Volume 18: 1.

Modern Approach to Nodal T-Cell Lymphomas

Sarah L. Ondrejka
Laurence de Leval

Advances in Anatomic Pathology (2025) 32 (3): 220.

Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma

Deepa Jagadeesh
Steve Horwitz
Nancy L Bartlett
Youn Kim
Eric Jacobsen
Madeleine Duvic
Meredith Little
William Trepicchio
Keenan Fenton
Matthew Onsum
Julie Lisano
Ranjana Advani

The Oncologist (2022) 27 (10): 864.